AU2002223599A1 - Pyrimidinone derivatives and their use in the treatment of atherosclerosis - Google Patents

Pyrimidinone derivatives and their use in the treatment of atherosclerosis

Info

Publication number
AU2002223599A1
AU2002223599A1 AU2002223599A AU2359902A AU2002223599A1 AU 2002223599 A1 AU2002223599 A1 AU 2002223599A1 AU 2002223599 A AU2002223599 A AU 2002223599A AU 2359902 A AU2359902 A AU 2359902A AU 2002223599 A1 AU2002223599 A1 AU 2002223599A1
Authority
AU
Australia
Prior art keywords
atherosclerosis
treatment
pyrimidinone derivatives
pyrimidinone
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002223599A
Inventor
Richard Leonard Elliott
Deirde Mary Bernadette Hickey
Robert John Ife
Colin Andrew Leach
Ivan Leo Pinto
Stephen Allen Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU2002223599A1 publication Critical patent/AU2002223599A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • C07D239/36One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/91Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
AU2002223599A 2000-10-10 2001-10-05 Pyrimidinone derivatives and their use in the treatment of atherosclerosis Abandoned AU2002223599A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0024807 2000-10-10
GBGB0024807.0A GB0024807D0 (en) 2000-10-10 2000-10-10 Novel compounds
PCT/EP2001/011562 WO2002030911A1 (en) 2000-10-10 2001-10-05 Pyrimidinone derivatives and their use in the treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
AU2002223599A1 true AU2002223599A1 (en) 2002-04-22

Family

ID=9901005

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002223599A Abandoned AU2002223599A1 (en) 2000-10-10 2001-10-05 Pyrimidinone derivatives and their use in the treatment of atherosclerosis

Country Status (11)

Country Link
US (2) US7169924B2 (en)
EP (1) EP1337517B1 (en)
JP (1) JP2004511473A (en)
AR (1) AR035068A1 (en)
AT (1) ATE415392T1 (en)
AU (1) AU2002223599A1 (en)
CA (1) CA2459746A1 (en)
DE (1) DE60136736D1 (en)
ES (1) ES2317949T3 (en)
GB (1) GB0024807D0 (en)
WO (1) WO2002030911A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060805A1 (en) * 2000-02-16 2001-08-23 Smithkline Beecham P.L.C. Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
GB0024807D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127139D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127140D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208279D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP1735457A4 (en) 2004-04-16 2007-08-29 Glaxo Group Ltd METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
CN101341128A (en) * 2005-12-23 2009-01-07 阿斯利康(瑞典)有限公司 Pyrazoles for the treatment of gerd and ibs
US20080090851A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US7705005B2 (en) * 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
US20080090852A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
WO2008048867A2 (en) * 2006-10-13 2008-04-24 Glaxo Group Limited Bicyclic heteroaromatic compounds
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
KR101461659B1 (en) 2007-05-11 2014-11-17 토마스 제퍼슨 유니버시티 Methods of treatment and prevention of neurodegenerative diseases and disorders
WO2008141176A1 (en) * 2007-05-11 2008-11-20 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
KR101931628B1 (en) 2010-06-18 2019-03-13 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Pla2g16 as a target for antiviral compounds
JP5886310B2 (en) 2010-12-06 2016-03-16 グラクソ グループ リミテッドGlaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2
EP2651403B1 (en) 2010-12-17 2020-12-02 Glaxo Group Limited Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
WO2012129792A1 (en) * 2011-03-30 2012-10-04 中国科学院上海药物研究所 Pyrimidinone compounds, preparation methods, pharmaceutical compositions and uses thereof
CN103619831B (en) 2011-06-27 2016-05-04 中国科学院上海药物研究所 Azole heterocyclic compound, its preparation method, pharmaceutical composition and purposes
RU2014107486A (en) 2011-07-27 2015-09-10 Глэксо Груп Лимитед Bicyclic pyrimidone compounds
BR112014001665A2 (en) 2011-07-27 2017-02-14 Glaxo Group Ltd 2,3-dihydroimidazo [1,2-c] pyrimidin-5 (1h) -one compounds used as lp-plaz inhibitors
FR2994184B1 (en) 2012-08-02 2017-12-08 Biomerieux Sa METHODS OF FUNCTIONALIZATION AND REAGENTS USED IN SUCH METHODS USING AN AZA-ISATOIC ANHYDRIDE OR ONE OF ITS DERIVATIVES, BIOLOGIC MOLECULES SO TREATED AND KITS
JP2016505053A (en) 2013-01-25 2016-02-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2
UY35276A (en) 2013-01-25 2014-08-29 Glaxosmithkline Ip Dev Ltd New compounds that inhibit the activity of Lp-PLA2
WO2014114248A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Compounds
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016198691A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica Ag Efflux-pump inhibitors and therapeutic uses thereof
CN111825695B (en) * 2019-04-15 2022-04-12 中国科学院上海药物研究所 Oxazolidinone compound, preparation method, application and pharmaceutical composition thereof
US11591840B1 (en) * 2019-10-31 2023-02-28 Andersen Corporation Power window operators, windows and methods
CN112778331B (en) 2019-11-09 2022-07-05 上海赛默罗生物科技有限公司 Tricyclic dihydroimidazopyrimidinone derivatives, preparation method, pharmaceutical composition and application thereof
CN115304620A (en) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 Pyrimidone derivatives, preparation method, pharmaceutical composition and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522844A (en) * 1997-11-06 2001-11-20 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Pyrimidinone compounds and pharmaceutical compositions containing them
WO2001060805A1 (en) * 2000-02-16 2001-08-23 Smithkline Beecham P.L.C. Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
GB0024807D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
US6649610B1 (en) * 2001-05-23 2003-11-18 University Of Central Florida 2-oxo-1, 4-benzoxazine compounds for treatment of tuberculosis

Also Published As

Publication number Publication date
GB0024807D0 (en) 2000-11-22
EP1337517A1 (en) 2003-08-27
ES2317949T3 (en) 2009-05-01
US20060241126A1 (en) 2006-10-26
AR035068A1 (en) 2004-04-14
CA2459746A1 (en) 2002-04-18
ATE415392T1 (en) 2008-12-15
JP2004511473A (en) 2004-04-15
US7169924B2 (en) 2007-01-30
US20040058941A1 (en) 2004-03-25
EP1337517B1 (en) 2008-11-26
WO2002030911A1 (en) 2002-04-18
DE60136736D1 (en) 2009-01-08
US7462620B2 (en) 2008-12-09

Similar Documents

Publication Publication Date Title
AU2002223599A1 (en) Pyrimidinone derivatives and their use in the treatment of atherosclerosis
AU2002225356A1 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
AU4171500A (en) Flupirtine in the treatment of fibromyalgia and related conditions
AU4289100A (en) Dihydropyrimidines and their use in the treatment of hepatitis
IL185461A0 (en) Pyrimidine compounds and their use
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
PL352330A1 (en) Derivatives of pyridopyranoazepine, making of same and use of same in therapy
AU2001281850A1 (en) Use of inulin and inulin derivatives
AU2001264258A1 (en) Nonwoven-fabric laminate and use thereof
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
AU2002247208A1 (en) Selective pde3b inhibitors and use of the same in therapy
AU2002211717A1 (en) Stresscopins and their uses
AU2001272011A1 (en) Siderophores-producing bifidobacteria thereby and uses thereof
HU0001396D0 (en) 3-amino-3-arylpropan-1-al derivatives and their use
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2002343103A1 (en) Aminoalkylimidazole derivatives and their use in medicine
AU2002243363A1 (en) Use of aziridino-compounds in the treatment of immune dysfunctions
AU7458201A (en) Laminate and use thereof
AU2001261750A1 (en) Laminate and its use
AU2001262149A1 (en) 2-(indanylamino)pyrimidone and 2-(tetrahydronaphthalenylamino)pyrimidone derivatives
AU2001252132A1 (en) Substituted 5-methyldihydropyridazinones and their use in the prophylaxis and/ortreatment of anemias
AU2001261375A1 (en) Human caspase-12 materials and methods
AU4129800A (en) Bis-benzazoles and their use as antineoplastic agents
AU2001241195A1 (en) Pyrimidinone derivatives and herbicides